TREM2 and the neuroimmunology of Alzheimer's disease
- PMID: 24355566
- PMCID: PMC3972304
- DOI: 10.1016/j.bcp.2013.11.021
TREM2 and the neuroimmunology of Alzheimer's disease
Abstract
Late-onset Alzheimer's disease (AD) is a sporadic disorder with increasing prevalence in aging. The ɛ4 allele of Apolipoprotein E(ApoEɛ4) was the only known major risk factor for late onset AD. Recently, two groups of investigators independently identified variants of the TREM2 gene, encoding triggering receptor expressed on myeloid cells 2 as causing increased susceptibility to late onset AD with an odds ratio similar to that of ApoEɛ4. TREM2 is a receptor expressed on innate immune cells. Using a novel technology called Direct RNA Sequencing wedetermined the quantitative transcriptome of microglia, the principal innate neuroimmune cells and confirmed that TREM2 is a major microglia-specific gene in the central nervous system. Over the past several years we have shown that microglia play a dichotomous role in AD. Microglia can be protective and promote phagocytosis, degradation and ultimately clearance of Aβ, the pathogenic protein deposited in the brains of Alzheimer's patients. However, with disease progression, microglia become dysfunctional, release neurotoxins, lose their ability to clear Aβ and produce pro-inflammatory cytokines that promote Aβ production and accumulation. TREM2 has been shown to regulate the phagocytic ability of myeloid cells and their inflammatory response. Here we propose that the mechanism(s) by which TREM2 variants cause Alzheimer's disease are via down regulation of the Aβ phagocytic ability of microglia and by dysregulation of the pro-inflammatory response of these cells. Based on our discussion we propose that TREM2 is a potential therapeutic target for stopping ordelaying progression of AD.
Keywords: Alzheimer's disease; Microglia; NeuroImmunology; TREM2.
Copyright © 2014 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
TREM2, Microglia, and Neurodegenerative Diseases.Trends Mol Med. 2017 Jun;23(6):512-533. doi: 10.1016/j.molmed.2017.03.008. Epub 2017 Apr 22. Trends Mol Med. 2017. PMID: 28442216 Review.
-
Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease.Brain Pathol. 2020 Jul;30(4):794-810. doi: 10.1111/bpa.12842. Epub 2020 Apr 29. Brain Pathol. 2020. PMID: 32267026 Free PMC article.
-
Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimer's Disease.J Alzheimers Dis. 2023;94(s1):S319-S333. doi: 10.3233/JAD-221070. J Alzheimers Dis. 2023. PMID: 36683512 Free PMC article. Review.
-
The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives.Int J Mol Sci. 2018 Dec 26;20(1):81. doi: 10.3390/ijms20010081. Int J Mol Sci. 2018. PMID: 30587772 Free PMC article. Review.
-
Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation.Neurobiol Aging. 2016 Jun;42:132-41. doi: 10.1016/j.neurobiolaging.2016.03.004. Epub 2016 Mar 16. Neurobiol Aging. 2016. PMID: 27143430 Free PMC article.
Cited by
-
Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer's disease (AD).J Nat Sci. 2015 Jul;1(7):e138. J Nat Sci. 2015. PMID: 26097896 Free PMC article.
-
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.Sci Transl Med. 2019 Aug 14;11(505):eaau2291. doi: 10.1126/scitranslmed.aau2291. Sci Transl Med. 2019. PMID: 31413141 Free PMC article.
-
Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease.Int Neurourol J. 2019 Nov;23(Suppl 2):S54-62. doi: 10.5213/inj.1938184.092. Epub 2019 Nov 30. Int Neurourol J. 2019. PMID: 31795604 Free PMC article.
-
Necroptosis and Neuroinflammation in Retinal Degeneration.Front Neurosci. 2022 Jun 29;16:911430. doi: 10.3389/fnins.2022.911430. eCollection 2022. Front Neurosci. 2022. PMID: 35844208 Free PMC article. Review.
-
Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?Expert Opin Ther Targets. 2018 Jul;22(7):587-598. doi: 10.1080/14728222.2018.1486823. Epub 2018 Jun 20. Expert Opin Ther Targets. 2018. PMID: 29889572 Free PMC article. Review.
References
-
- Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98. - PubMed
-
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102. - PubMed
-
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–21. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous